Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CYDY has the same flat pattern today b(but at just below $6). Strange.
Ec: "I usually visit my primary care physician when I feel a cold coming on"
You do? Why?
He's been unrelentingly enthusiastic about the chemistry and general effectiveness since months ago. I wonder what he's up to tonight?
These are great wuestions, gfp927z, and I guess we'll find out the answers soon. But we can do a little pre-game prognosticating right now.
Hear, hear! A perfecta for leronlimab, m/m now and in a week or two DSMB intervenes to cut short the s/c trials to give leronlimab to the placebo arm to save lives.
the idea is that leronlimab PREVENTS the cytokine storm, so m/m cases do not progress, turning covid-19 into a bad cold. Placebo patients are unprotected and separated from leronlimab patients because some get worse and many do not get better as fast. Leronlimab for the win.
The s/c cases might not be so clear because reversing the cytokine storm is harder than preventing it.
nice...how many shares?
We are all so, SO conceroned!
Actually, not at all. This is an "investors" board, not a "traders" board and much more interested in material news about the compaony.
and then release the good news, and shorts will lose their pants!
yep...NIAID was the sponsor of the study. They wanted the rem test to look good and went all out to set it up. Corruption via advocacy? Well, if they can get away with it! I'm not saying that anything is truly awry, but it does look fishy. Not for money interest, though, but for interest in a particular story or reputation, namely, that "there's hope and the feds are helping bring it to you fast."
I really do not think Fauci (or virtually any gov't scientist) uses money as a currency for keeping score. With them, it's all about whose ideas win, not whose wallets win.
For industry, follow the money.
For science, follow the idea/ideology/reputation.
For gov't, follow the power.
If the idea is, "I'm the boss of NIAID. We need some good news." There's a temptation to subordinate the interest of good science to the interest of good news. That's the corrupting influence of advocacy, which is a MUCH bigger threat to science than the corrupting influence of money.
dropping b/c we are on the verge of getting significant news...ideal conditions for shorts. If they can move the price down a little andgenerate a fear that someone knows something, skittish investors will give up their shares for very little.
I expect we'll get hit pretty hard in a couple coordinated attacks before we get news. It would be awesome if they coordinated a massive short attack that dropped the price way down, and then great news were released and the price gapped way, way up, leaving the naked shorters without any shares, drained accounts, and a consolation prize of free maintenance in a room with bars on the window but no view.
The feds have a thick rule book for ethics. I don't know anything about Fauci in particular, but I do know and work with a lot of federal GS-12+ scientists, and, as a group, they are almost obsessed with compliance. Owning pharma stock or having a financial interest in any med company would be an obvious and gross ethical violation.
Scientists are certainly not immune to corruption, but the biggest corrupter is advocacy, not money. For federal scientists, the next biggest danger is lust for power, as the infatuation with compliance spills over into wanting control over other people.
It's almost inconceivable to me that Fauci has big investments in big pharma. Corrupt? Possibly, but it would be by an advocacy pathway rather than a money pathway.
Yes, you could bet money that Fauci has big investments in big pharma, but it's a bet you would surely lose.
Rem is Fauci's encore after AZT
If you start with 1 primary outcome and 17 secondary outcomes but are allowed to change the primary outcome to whichever of the secondary outcomes you like late, late in the trial, then there'd be a 1-0.95^18 = 60% chance that the chicken soup would show a "significant effect" ...just like remdesivir did.
I suspect leronlimab will show p < 0.05 on primary outcome and most of the secondary outcomes.
week of August 17-21
no. MM announced it "unofficially" in the CC Monday
but not without last year's financials first? accounting may not be ready with the paperwork for a few more weeks...
Thanks for your indefatigable research on the critical issue, justdafactss. Thanks to all your hard work thinking about it, the rest of us can afford to think about other things now...so liberating!
excepting naked shorts
This is truly amazing insight, justdafactss. NP's work history is very important to the company and investors. Just think...what if he worked somewhere like McDonald's or JP Morgan before he came to CYDY a decade or so ago? I'm sure that would spell curtains for the clinical trials and uplisting.
This is a truly fascinating and profound question, justdafactss. I sure hope someone will take it seriously and resolve the issue once and for all.
"Everyone knows it's holders of shares doing the dumping"---a fascinating, most-certainly-true fact, dat one! There's not a single person who doesn't know. But, just in case, it would be great to see evidentiary support. Can you provide a reputable link or a more robust analysis?
They wanted more data and got it. The data are good, but apparently the analysis is lacking in some respect.
be careful with language
I believe the word he used yesterday was "expect". The problem is in his expressed expectations being unmet over and over again, to the detriment of his credibility.
bleach definitely kills coronavirus!
In theory, it is easy to solve any single problem.
well, to be fair, SP is up over 50% in the past month, which isn't quite as high as it was a week or so ago. C'est la vie. That's life in the pre-revenue biotech lane.
News coming soon, so load up now while you have a chance. And if you like shorting, make the most of these last days before SP gaps up on real news and you're left holding the bag.
We've seen really obvious pattern trading for coordinated short attacks lately. CYDY management makes it easy for them by giving shifting, muddled stories that provide perfect conditions for sowing doubt.
me too
HGEN's bubble may be popping...they had a huge, rapid run-up on rumors but no news due for a few months.
We had a huge, rapid run-up on rumors too, but news is imminent (or so we were led to believe...PDUFA, trials, uplisting).
This is garbage. He mentioned Dr BP in today's webinar, saying he was doing the blood work for the studies. Some other goofy speculations could be made too: he hasn't mentioned Michael Mulholland in awhile; there must be something bad between them? Ditto for Nitya Ray. Pure FUD.
I didn't hear him mention it today...maybe I missed it? Also, someone asked about it specifically in the last call, and he deflected, bringing up the other three researchers instead.
Normally, scientists are good spellers because they tend to be careful and observant, but I have met two scientists who were not good spellers...one was not very careful and focused more on teaching, the other was a odd-ball who may have spelled things how he wished they were spelled.
Papers...he didn't mention Dr. Patterson's but did mention papers by Seethamraju at Montefiore (with the same patient cohort that BP's draft manuscript addressed), Otto Yang at UCLA, and Nicholas Agresti in Atlanta.
I'm guessing that Dr. BP passed the reins to Seethamraju for finishing the MS.
NP confirmed tomorrow for PDUFA.
What a pathetic outfit this "Wall Street Reporter" is, especially this particular interviewer. Bleah.
Sara, agreed that lenzilumab is a more compelling competitor than tocilizumab, but if even non-competitor tocilizumab can show much stronger results than SOC for severe cases, what about the real drug leronlimab? I'd guess that it does at least as well as tocilizumab => good leronlimab results for s/c. I am already pretty confident about the m/m trials looking good. m/m + s/c = a big win for leronlimab in its progress through the pipeline.
Leronlimab for the win...
A recent retrospective study of the IL-6 antagonist tocilizumab in critical covid-19 cases should huge decrease in mortality compared to SOC (7% versus 20%, p-value < 0.0001), but as might be expected with tocilizumab, more patients in the treatment group (13%) than in the SOC group (4%) were diagnosed with new infections (p-value < 0.0001).
So a simple IL-6 blocker with a reputation for increasing the risk of secondary infections saved lives by blocking IL-6 but was associated with new infections.
I've been optimistic about leronlimab in m/m cases because it very likely can reduce the risk of the disease progressing to more serious cases. The s/c cases are much more difficult, but if a simple IL-6 blocker shows this strong of an effect, leronlimab should be able to help in those cases too---and without the new infections!
Big win for leronlimab and CYDY...excited to see the upcoming results.